About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine, AURYXIA® (ferric citrate) tablets. Patients have been and continue to be at the center of our 17-year corporate history.
Keryx established its corporate headquarters in Boston to support the U.S. launch of AURYXIA. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 185 full-time employees across Boston and our field team.
|
|
|
11-50 employees
View all Keryx Biopharmaceuticals employees
|
|
Biotechnology
|
|
US
|
|
Renal Disease
|
Keryx Biopharmaceuticals Alternatives
Frequently Asked Questions about Keryx Biopharmaceuticals
Dele Momo is the CEO of Keryx Biopharmaceuticals.
Keryx Biopharmaceuticals Staff Directory
Search Keryx Biopharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
